Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | BAX | Q07812 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31083394 | 0.77 | PTGS1 (0.48) | TSHRALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL25355309 | 0.76 | SCN5A (0.36) | MAPTSMN1; SMN2LMNACYP1A2CYP3A4 | |
| SCHEMBL31409587 | 0.76 | SLC6A4 (0.38) | LTA4HLMNAKDM4ERAB9AL3MBTL1 | |
| SCHEMBL12475977 | 0.72 | MLYCD (0.51) | LTA4HTSHRMLYCDALDH1A1POLB | |
| SCHEMBL9362428 | 0.68 | LTA4H (0.46) | LTA4HTSHRMLYCDBCAT2MAPT | |
| SCHEMBL6122699 | 0.68 | NPC1 (0.42) | LTA4HTSHRMLYCDALDH1A1MAPT | |
| SCHEMBL6264790 | 0.67 | LTA4H (0.44) | LTA4HTSHRMLYCDBCAT2MAPT | |
| Diphenylether SCHEMBL9061108 | 0.65 | LTA4H (1.00) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL2461810 | 0.65 | LTA4H (1.00) | LTA4HTSHRNR1H2BAXMAOA | |
| Diphenylether SCHEMBL12286 | 0.65 | LTA4H (1.00) | LTA4HTSHRNR1H2BAXMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023006097-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | 海创药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| EP-2099795-B1 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBVIE BAHAMAS LTD (BS) | 2015-08-19 | — | — | EP | disclosed |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES | 2015-06-11 | — | — | US | disclosed |
| US-8987453-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130096132-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8314119-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2099795-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | Abbott Laboratories (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008058096-A9 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LAB (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008058096-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096132-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | LTA4H 1194/4885TSHR 1089/4885MLYCD 2540/4885 |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | HTT, ACHE, CHRNA10 | LTA4H 3075/4885TSHR 3040/4885MLYCD 3082/4885 |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | LTA4H 1194/4885TSHR 1089/4885MLYCD 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.